baclofen has been researched along with Apoplexy in 36 studies
Excerpt | Relevance | Reference |
---|---|---|
"Intrathecal baclofen (ITB) is a treatment option for patients with severe poststroke spasticity (PSS) who have not reached their therapy goal with other interventions." | 9.27 | Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS). ( Abouihia, A; Berthuy, N; Calabrese, A; Cloud, G; Creamer, M; Francisco, GE; Kossmehl, P; Loven, M; Saltuari, L; Ward, AB; Wissel, J; Yochelson, M; Zampolini, M, 2018) |
"Background and Purpose- Intrathecal baclofen (ITB) is an effective treatment for managing patients with severe poststroke spasticity, who can experience continued pain and decline in their quality of life (QoL)." | 9.27 | Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity. ( Abouihia, A; Calabrese, A; Cloud, G; Creamer, M; Francisco, GE; Kossmehl, P; Saltuari, L; Ward, AB; Wissel, J; Yochelson, M; Zampolini, M, 2018) |
"In total, 30 stroke patients with persistent hiccups were randomly assigned to receive baclofen (n = 15) or a placebo (n = 15) in a double-blind, parallel-group trial." | 9.19 | Baclofen for stroke patients with persistent hiccups: a randomized, double-blind, placebo-controlled trial. ( Xu, M; Zhang, C; Zhang, R; Zhang, S, 2014) |
"To evaluate the impact of intrathecal baclofen (ITB) on function and quality of life (QOL) and to obtain efficacy and safety data in poststroke spastic hypertonia." | 9.12 | Intrathecal baclofen management of poststroke spastic hypertonia: implications for function and quality of life. ( Francisco, GE; Grissom, SP; Ivanhoe, CB; McGuire, JR; Subramanian, T, 2006) |
"To explore whether intrathecal baclofen (ITB) therapy improves ambulation in stroke survivors." | 9.10 | Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: a preliminary study. ( Boake, C; Francisco, GE, 2003) |
"Intrathecal infusion of baclofen is capable of maintaining a reduction in the spastic hypertonia resulting from stroke." | 9.09 | Intrathecal baclofen for spastic hypertonia from stroke. ( Brunner, RC; Guin-Renfroe, S; Hadley, MN; Meythaler, JM, 2001) |
"This chapter will review the application of intrathecal baclofen (ITB) in the management of post-stroke hypertonia, a major complication that results in deformity and discomfort, and limits mobility and performance of activities of daily living (ADL)." | 8.84 | Intrathecal baclofen in the management of post-stroke hypertonia: current applications and future directions. ( Francisco, GE, 2007) |
"Intrathecal baclofen (ITB) therapy has been increasingly employed for the management of poststroke spastic hypertonia, a complication that can lead to deformity, discomfort, and exacerbation of motor impairments." | 8.83 | Consensus panel guidelines for the use of intrathecal baclofen therapy in poststroke spastic hypertonia. ( Cavalier, S; Francisco, GE; Grissom, S; Schiess, MC; Wiggs, L; Yablon, SA, 2006) |
"Objective To assess quantitatively the efficacy of oral baclofen for spasticity poststroke." | 7.88 | Effect of oral baclofen on spasticity poststroke: responders versus non-responders. ( Maeshima, S; Mizuno, S; Shigeru, S; Takeda, K, 2018) |
"To assess the effects of intrathecal baclofen (ITB) therapy for the treatment of poststroke spastic hemiparesis on quality of life, functional independence, and upper, lower extremity (UE, LE) motor functions." | 7.77 | Prospective 12-month study of intrathecal baclofen therapy for poststroke spastic upper and lower extremity motor control and functional improvement. ( Acosta, F; Fisher, S; Lucke, J; Oh, IJ; Schiess, MC; Simpson, RK; Stimming, EF, 2011) |
"To determine whether intrathecal administration of baclofen reduced spastic hypertonia in a hemiplegic patient after hemorrhagic stroke." | 7.74 | [Efficacy of intrathecal baclofen in the treatment of spasticity in stroke]. ( Cantalloube, S; Lamotte, D, 2007) |
"To determine whether leg muscle stiffness is measurably reduced after intrathecal baclofen (ITB) in subjects with spastic hemiplegia." | 7.72 | Intrathecal baclofen in subjects with spastic hemiplegia: assessment of the antispastic effect during gait. ( Bouilland, S; Bussel, B; Rémy-Néris, O; Tiffreau, V, 2003) |
"This study was undertaken to determine the efficacy of intrathecal baclofen therapy in patients who suffer spasticity after a stroke." | 7.71 | Intrathecal baclofen for spasticity caused by thrombotic stroke. ( Gwartz, BL, 2001) |
"The mean daily dosage alleviating spasticity on the hemiparetic side-without affecting the nonparetic side-was 119 microg/day (range 50 to 360 microg/day)." | 6.74 | Limitations of intrathecal baclofen for spastic hemiparesis following stroke. ( Kofler, M; Quirbach, E; Saltuari, L; Schauer, R; Singer, M, 2009) |
"Sporadic cases of dramatic recovery from persistent vegetative state after intrathecal administration of baclofen have been reported." | 6.44 | Intrathecal baclofen in the treatment of post-stroke central pain, dystonia, and persistent vegetative state. ( Hori, T; Taira, T, 2007) |
"To study the electromiographic (EMG) parameters and to evaluate the therapeutic efficacy of a combination of central (baclofen, baclosan) and peripheral (incobotulotoxinA, xeomin) muscle relaxants in the treatment of post-stroke spasticity (PSS)." | 5.30 | [Combination of central and peripheral muscle relaxants in the treatment of post-stroke spasticity]. ( Frunza, DN; Iskra, DA; Koshkarev, MA; Kovalenko, AP, 2019) |
"Intrathecal baclofen (ITB) is a treatment option for patients with severe poststroke spasticity (PSS) who have not reached their therapy goal with other interventions." | 5.27 | Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS). ( Abouihia, A; Berthuy, N; Calabrese, A; Cloud, G; Creamer, M; Francisco, GE; Kossmehl, P; Loven, M; Saltuari, L; Ward, AB; Wissel, J; Yochelson, M; Zampolini, M, 2018) |
"Background and Purpose- Intrathecal baclofen (ITB) is an effective treatment for managing patients with severe poststroke spasticity, who can experience continued pain and decline in their quality of life (QoL)." | 5.27 | Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity. ( Abouihia, A; Calabrese, A; Cloud, G; Creamer, M; Francisco, GE; Kossmehl, P; Saltuari, L; Ward, AB; Wissel, J; Yochelson, M; Zampolini, M, 2018) |
"In total, 30 stroke patients with persistent hiccups were randomly assigned to receive baclofen (n = 15) or a placebo (n = 15) in a double-blind, parallel-group trial." | 5.19 | Baclofen for stroke patients with persistent hiccups: a randomized, double-blind, placebo-controlled trial. ( Xu, M; Zhang, C; Zhang, R; Zhang, S, 2014) |
"To evaluate the impact of intrathecal baclofen (ITB) on function and quality of life (QOL) and to obtain efficacy and safety data in poststroke spastic hypertonia." | 5.12 | Intrathecal baclofen management of poststroke spastic hypertonia: implications for function and quality of life. ( Francisco, GE; Grissom, SP; Ivanhoe, CB; McGuire, JR; Subramanian, T, 2006) |
"To explore whether intrathecal baclofen (ITB) therapy improves ambulation in stroke survivors." | 5.10 | Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: a preliminary study. ( Boake, C; Francisco, GE, 2003) |
"Intrathecal infusion of baclofen is capable of maintaining a reduction in the spastic hypertonia resulting from stroke." | 5.09 | Intrathecal baclofen for spastic hypertonia from stroke. ( Brunner, RC; Guin-Renfroe, S; Hadley, MN; Meythaler, JM, 2001) |
"This chapter will review the application of intrathecal baclofen (ITB) in the management of post-stroke hypertonia, a major complication that results in deformity and discomfort, and limits mobility and performance of activities of daily living (ADL)." | 4.84 | Intrathecal baclofen in the management of post-stroke hypertonia: current applications and future directions. ( Francisco, GE, 2007) |
"Intrathecal baclofen (ITB) therapy has been increasingly employed for the management of poststroke spastic hypertonia, a complication that can lead to deformity, discomfort, and exacerbation of motor impairments." | 4.83 | Consensus panel guidelines for the use of intrathecal baclofen therapy in poststroke spastic hypertonia. ( Cavalier, S; Francisco, GE; Grissom, S; Schiess, MC; Wiggs, L; Yablon, SA, 2006) |
"Objective To assess quantitatively the efficacy of oral baclofen for spasticity poststroke." | 3.88 | Effect of oral baclofen on spasticity poststroke: responders versus non-responders. ( Maeshima, S; Mizuno, S; Shigeru, S; Takeda, K, 2018) |
"To assess the effects of intrathecal baclofen (ITB) therapy for the treatment of poststroke spastic hemiparesis on quality of life, functional independence, and upper, lower extremity (UE, LE) motor functions." | 3.77 | Prospective 12-month study of intrathecal baclofen therapy for poststroke spastic upper and lower extremity motor control and functional improvement. ( Acosta, F; Fisher, S; Lucke, J; Oh, IJ; Schiess, MC; Simpson, RK; Stimming, EF, 2011) |
"To determine whether intrathecal administration of baclofen reduced spastic hypertonia in a hemiplegic patient after hemorrhagic stroke." | 3.74 | [Efficacy of intrathecal baclofen in the treatment of spasticity in stroke]. ( Cantalloube, S; Lamotte, D, 2007) |
"To determine whether leg muscle stiffness is measurably reduced after intrathecal baclofen (ITB) in subjects with spastic hemiplegia." | 3.72 | Intrathecal baclofen in subjects with spastic hemiplegia: assessment of the antispastic effect during gait. ( Bouilland, S; Bussel, B; Rémy-Néris, O; Tiffreau, V, 2003) |
"This study was undertaken to determine the efficacy of intrathecal baclofen therapy in patients who suffer spasticity after a stroke." | 3.71 | Intrathecal baclofen for spasticity caused by thrombotic stroke. ( Gwartz, BL, 2001) |
"Adults (N=28) with muscle hypertonia due to stroke, trauma, or anoxia." | 2.75 | Effect of intrathecal baclofen bolus injection on lower extremity joint range of motion during gait in patients with acquired brain injury. ( Chow, JW; Horn, TS; Lee, JE; Stokic, DS; Yablon, SA, 2010) |
"The mean daily dosage alleviating spasticity on the hemiparetic side-without affecting the nonparetic side-was 119 microg/day (range 50 to 360 microg/day)." | 2.74 | Limitations of intrathecal baclofen for spastic hemiparesis following stroke. ( Kofler, M; Quirbach, E; Saltuari, L; Schauer, R; Singer, M, 2009) |
"Sporadic cases of dramatic recovery from persistent vegetative state after intrathecal administration of baclofen have been reported." | 2.44 | Intrathecal baclofen in the treatment of post-stroke central pain, dystonia, and persistent vegetative state. ( Hori, T; Taira, T, 2007) |
"TTC staining was used to detect cerebral infarction volume, and the brain water content of rats in each group was determined by wet and dry weight method." | 1.91 | [Effects of Governor Vessel electroacupuncture on chloridion homeostasis in the cortex of rats with limb spasm after cerebral ischemia-reperfusion]. ( Guo, J; Li, JW; Li, RQ; Mei, JJ; Wang, YY; Zhang, JY; Zhang, LH, 2023) |
" A complex dosing pattern was used more frequently in those with stroke (36." | 1.46 | Long-Term Dosing of Intrathecal Baclofen in the Treatment of Spasticity After Acquired Brain Injury. ( Maneyapanda, MB; Marciniak, C; McCormick, ZL; Reger, C, 2017) |
"Significant differences in dosing were found between diagnoses and trended to differ by ambulatory status at the end of the study, and similar trends could be observed in achieving initial stable dose." | 1.43 | Intrathecal Baclofen Dosing Regimens: A Retrospective Chart Review. ( Clearfield, JS; McGuire, J; Nelson, ME; Rein, LE; Tarima, S, 2016) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 17 (47.22) | 29.6817 |
2010's | 16 (44.44) | 24.3611 |
2020's | 3 (8.33) | 2.80 |
Authors | Studies |
---|---|
Cinone, N | 1 |
Santoro, L | 1 |
Spina, S | 1 |
Facciorusso, S | 1 |
Battaglia, M | 1 |
Baricich, A | 1 |
Marcogiuseppe, P | 1 |
Santamato, A | 1 |
Wang, YY | 1 |
Li, RQ | 1 |
Li, JW | 1 |
Mei, JJ | 1 |
Zhang, LH | 1 |
Zhang, JY | 1 |
Guo, J | 1 |
Iskra, DA | 1 |
Kovalenko, AP | 1 |
Koshkarev, MA | 1 |
Frunza, DN | 1 |
Surathi, P | 1 |
Sher, J | 1 |
Obaydou, N | 1 |
Pergament, KM | 1 |
Creamer, M | 2 |
Cloud, G | 2 |
Kossmehl, P | 2 |
Yochelson, M | 2 |
Francisco, GE | 7 |
Ward, AB | 2 |
Wissel, J | 2 |
Zampolini, M | 2 |
Abouihia, A | 2 |
Berthuy, N | 1 |
Calabrese, A | 2 |
Loven, M | 1 |
Saltuari, L | 3 |
Mizuno, S | 1 |
Takeda, K | 1 |
Maeshima, S | 1 |
Shigeru, S | 1 |
Lipták, J | 1 |
Chow, JW | 2 |
Yablon, SA | 3 |
Stokic, DS | 2 |
Zhang, C | 1 |
Zhang, R | 1 |
Zhang, S | 2 |
Xu, M | 1 |
Rush, R | 1 |
Kumbhare, D | 1 |
Clearfield, JS | 1 |
Nelson, ME | 1 |
McGuire, J | 1 |
Rein, LE | 1 |
Tarima, S | 1 |
Niehaus, MT | 1 |
Elliott, NC | 1 |
Katz, KD | 1 |
Lindsay, C | 1 |
Kouzouna, A | 1 |
Simcox, C | 1 |
Pandyan, AD | 1 |
Maneyapanda, MB | 1 |
McCormick, ZL | 1 |
Marciniak, C | 1 |
Reger, C | 1 |
Agarwal, S | 1 |
Patel, T | 1 |
Shah, N | 1 |
Patel, BM | 1 |
Kofler, M | 1 |
Quirbach, E | 1 |
Schauer, R | 1 |
Singer, M | 1 |
Huang, YS | 1 |
Hsiao, MC | 1 |
Lee, M | 1 |
Huang, YC | 1 |
Lee, JD | 1 |
Horn, TS | 1 |
Lee, JE | 1 |
Schiess, MC | 2 |
Oh, IJ | 1 |
Stimming, EF | 1 |
Lucke, J | 1 |
Acosta, F | 1 |
Fisher, S | 1 |
Simpson, RK | 1 |
Turner, M | 1 |
Nguyen, HS | 1 |
Cohen-Gadol, AA | 1 |
Rémy-Néris, O | 1 |
Tiffreau, V | 1 |
Bouilland, S | 1 |
Bussel, B | 1 |
Boake, C | 2 |
Yelnik, AP | 1 |
Smith, J | 1 |
Hu, MM | 1 |
Ivanhoe, CB | 2 |
Choudhuri, I | 1 |
Sarvananthan, N | 1 |
Gottlob, I | 1 |
Wiggs, L | 1 |
Cavalier, S | 1 |
Grissom, S | 1 |
McGuire, JR | 1 |
Subramanian, T | 1 |
Grissom, SP | 1 |
Lamotte, D | 1 |
Cantalloube, S | 1 |
Deer, TR | 1 |
Raso, LJ | 1 |
Garten, TG | 1 |
Taira, T | 1 |
Hori, T | 1 |
Abramson, SI | 1 |
Holmes, AA | 1 |
Hagberg, CA | 1 |
Gwartz, BL | 1 |
Meythaler, JM | 1 |
Guin-Renfroe, S | 1 |
Brunner, RC | 1 |
Hadley, MN | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomized, Controlled, Open-label, Parallel-group, Multi-center Study to Compare the Effect of Intrathecal Baclofen Therapy Versus Best Medical Treatment on Severe Spasticity in Post-stroke Patients After 6 Months Active Treatment[NCT01032239] | Phase 4 | 61 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
Effects of Neuromuscular Electrical Stimulation on Walking Ability and Quality of Life in Individuals With Chronic Stroke[NCT04673045] | 40 participants (Anticipated) | Interventional | 2021-02-02 | Recruiting | |||
Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187] | 8 participants (Actual) | Interventional | 2009-11-30 | Terminated (stopped due to PI left institution) | |||
Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS): A Randomized, Controlled, Multi-center, Prospective Study Evaluating Dose Reduction in ITB Patients.[NCT04530955] | 92 participants (Anticipated) | Interventional | 2020-09-24 | Recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Change in average 10MTWT from baseline to month 6 beetween ITB and BMT arm. Change=10MTWT at month 6 - 10MTWT at baseline (NCT01032239)
Timeframe: Baseline and month 6
Intervention | seconds (Mean) |
---|---|
ITB Therapy | 4.86 |
Best Medical Treatment (BMT) | -2.48 |
"AS is a manual test, measuring the resistance to passive movement about a joint with varying degrees of velocity. Scores range from 1-5, with 5 choices. A score of 1 indicates no resistance, and 5 indicates rigidity. The following muscle groups in the lower extremities were assessed: hip flexors, hip adductors, knee extensors, knee flexors, plantar flexors and ankle-dorsal flexors. Average AS was calculated as the average of AS scores of the 6 muscles of the affected lower extremity. Change in average AS in affected lower extremities from baseline to month 6 between ITB and BMT arm was assessed.~Change= AS at month 6 - AS at baseline." (NCT01032239)
Timeframe: Baseline and month 6
Intervention | units on a scale (Mean) |
---|---|
ITB Therapy | -0.99 |
Best Medical Treatment (BMT) | -0.43 |
"AS is a manual test, measuring the resistance to passive movement about a joint with varying degrees of velocity. Scores range from 1-5, with 5 choices. A score of 1 indicates no resistance, and 5 indicates rigidity. The following muscle groups in the upper extremities were assessed: wrist flexors, elbow flexors, elbow extensors, shoulder abductors and shoulder adductors. Average AS was calculated as the average of AS scores of the 5 muscles of the affected lower extremities. Change in average AS in affected upper extremities from baseline to month 6 between ITB and BMT arm was assessed.~Change= AS at month 6 - AS at baseline." (NCT01032239)
Timeframe: Baseline and month 6
Intervention | units on a scale (Mean) |
---|---|
ITB Therapy | -0.66 |
Best Medical Treatment (BMT) | -0.17 |
FIM contains 18 items composed of 13 motor tasks and 5 cognitive tasks. Tasks are rated on a 7-point ordinal scale that ranges from total assistance (or complete dependence) to complete independence. Ratings should reflect actual observed performance, not capability. Total score ranges from 18 (lowest) to 126 (highest) level of independence. Change in FIM total score from baseline to month 6 between ITB and BMT arm was assessed. Change=FIM score at month 6 - FIM score at baseline. (NCT01032239)
Timeframe: Baseline and month 6
Intervention | units on a scale (Mean) |
---|---|
ITB Therapy | 2.68 |
Best Medical Treatment (BMT) | -2.58 |
"SS-QoL questionnaire is a self-assessed quality of life questionnaire specifically designed for post-stroke patients. It evaluates 49 items across 12-domains: personality, energy, language, mobility, vision, upper extremity function, thinking, mood, work/productivity, self-care, and family and social roles. Each item is rated on a 5-point Likert Scale, measuring either positive or negative response to a statement. Summary score is composed of an unweighted average of the 12 domain scores, with higher scores indicating better QoL. Total score ranges from 1 to 5. Change in SS-QoL summary score from baseline to month 6 between ITB and BMT arm was assessed.~Change=SS-QoL score at month 6 - SS-QoL score at baseline." (NCT01032239)
Timeframe: Baseline and month 6
Intervention | units on a scale (Mean) |
---|---|
ITB Therapy | 0.26 |
Best Medical Treatment (BMT) | 0.05 |
"The EQ-5D-3L is a generic measure of health status consisting in the EQ-5D-3L descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system is characterized on five dimensions: mobility, self-care, ability to undertake usual activities, pain and anxiety/depression. Patients were asked to indicate their level of health on each dimension using one of three levels: no health problems, moderate health problems, and severe health problems. Responses from the questionnaire were converted to a single health index utility score; this ranges from -0.595 to 1. EQ VAS records the patient's self-rated health on a vertical visual analogue scale from 0 to 100 where the endpoints are labelled 'Best imaginable health state' (100) and 'Worst imaginable health state' (0). Change in EQ-5D-3L utility score and VAS score from baseline to month 6 between ITB and BMT arm were assessed. Change=EQ-5D-3L utility or VAS score at month 6 - EQ-5D-3L utility or VAS score." (NCT01032239)
Timeframe: Baseline and month 6
Intervention | units on a scale (Mean) | |
---|---|---|
Utility Score | VAS | |
Best Medical Treatment (BMT) | 0.01 | 4.40 |
ITB Therapy | 0.09 | 9.68 |
"NPRS is designed to assess the level of pain a patient is feeling at a point in time. The following questions has been presented to patients: What is your actual spasticity-related or spasm-related pain? What was your least spasticity-related or spasm-related pain during the last week? What was your worst spasticity-related or spasm-related pain during the last week? The patient indicated how much pain he is feeling on a scale from 0 to 10. A score of 0 (zero) is no pain while a score of 10 (ten) is worst possible pain. Change in NPRS related to actual, least or worst pain from baseline to month 6 between ITB and BMT arm was assessed. Change=NPRS at month 6 - NPRS at baseline." (NCT01032239)
Timeframe: Baseline and month 6
Intervention | units on a scale (Mean) | ||
---|---|---|---|
Actual pain | Least Pain | Worst Pain | |
Best Medical Treatment (BMT) | 0.00 | 0.24 | -0.04 |
ITB Therapy | -1.17 | -1.61 | -1.35 |
The SF-12 is generic assessment of health-related quality of life, which evaluates 8 health dimensions (physical functioning, role physical, bodily pain, vitality, social functioning, role emotional, mental health, and general health). Subscale scores for each dimension were aggregated into summary scores for physical (PCS) and mental health (MCS) components (ranging from 0 to 100, with higher scores indicating better health). Changes in the PCS and MCS from baseline to Month 6 were both compared between the BMT and ITB arms. Change=SF-12 score at month 6 - SF-12 score at baseline. (NCT01032239)
Timeframe: Baseline and month 6
Intervention | units on a scale (Mean) | |
---|---|---|
PCS | MCS | |
Best Medical Treatment (BMT) | -1.13 | -0.82 |
ITB Therapy | 3.13 | 1.05 |
Number of patients with healthcare professional contacts outside of study visits in the ITB and BMT between baseline and months 6 (NCT01032239)
Timeframe: baseline, ITB test (only ITB arm), second assessment (only BMT arm), week 6 (only ITB arm), month 3, month 6
Intervention | Participants (Count of Participants) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline : general practitioner | Baseline : neurologist | Baseline : nurse (hospital setting) | Baseline : nurse (home care) | Baseline : orthopedic surgeon | Baseline : other | ITB test:general practitioner | ITB test: neurologist | ITB test :other | Second Assessment: general practitioner | Second Assessment: neurologist | Second Assessment: nurse (home care) | Second Assessment: other | week 6: general practitioner | week 6: nurse (hospital setting) | week 6: other | month 3: general practitioner | month 3: neurologist | month 3: other | month 6: general practitioner | month 6: neurologist | month 6: other | |
Best Medical Treatment (BMT) | 8 | 8 | 0 | 1 | 0 | 13 | NA | NA | NA | 5 | 1 | 1 | 4 | NA | NA | NA | 8 | 3 | 9 | 7 | 2 | 11 |
ITB Therapy | 14 | 4 | 1 | 0 | 3 | 10 | 1 | 1 | 3 | NA | NA | NA | NA | 4 | 2 | 2 | 7 | 1 | 6 | 8 | 3 | 8 |
Patient was asked to transfer from the wheelchair to bed without human assistance. High level functional patient (HLP) could transfer. Low level functional patient (LLP) was not able to transfer. Comparison of the number and percentage of HLP and LLP between ITB and BMT arms was evaluated. (NCT01032239)
Timeframe: baseline, month 3, month 6
Intervention | Participants (Count of Participants) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline72364475 | Baseline72364476 | Month 372364475 | Month 372364476 | Month 672364475 | Month 672364476 | |||||||
HLP | LLP | |||||||||||
ITB Therapy | 22 | |||||||||||
Best Medical Treatment (BMT) | 24 | |||||||||||
ITB Therapy | 9 | |||||||||||
Best Medical Treatment (BMT) | 21 | |||||||||||
ITB Therapy | 6 | |||||||||||
ITB Therapy | 19 | |||||||||||
Best Medical Treatment (BMT) | 19 | |||||||||||
ITB Therapy | 5 | |||||||||||
Best Medical Treatment (BMT) | 5 |
"Patients were presented with two statements (I am satisfied with the reduction in spasticity provided by my treatment, and I would recommend this therapy to a friend). They agreed, disagreed or were neutral with the statements." (NCT01032239)
Timeframe: month 6
Intervention | Participants (Count of Participants) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Patient Satisfaction with Spasticity Reduction72364475 | Patient Satisfaction with Spasticity Reduction72364476 | Patient Therapy Reccomandation72364475 | Patient Therapy Reccomandation72364476 | |||||||||
disagree | neutral | agree | ||||||||||
ITB Therapy | 2 | |||||||||||
Best Medical Treatment (BMT) | 7 | |||||||||||
ITB Therapy | 4 | |||||||||||
ITB Therapy | 16 | |||||||||||
Best Medical Treatment (BMT) | 11 | |||||||||||
Best Medical Treatment (BMT) | 5 | |||||||||||
ITB Therapy | 3 | |||||||||||
Best Medical Treatment (BMT) | 4 | |||||||||||
Best Medical Treatment (BMT) | 14 |
5 reviews available for baclofen and Apoplexy
Article | Year |
---|---|
Pharmacological interventions other than botulinum toxin for spasticity after stroke.
Topics: Baclofen; Botulinum Toxins, Type A; Clonidine; Diazepam; Humans; Muscle Relaxants, Central; Muscle S | 2016 |
[Pharmacology and upper limb poststroke spasticity: a review. International Society of Prosthetics and Orthotics].
Topics: Arm; Baclofen; Botulinum Toxins, Type A; Clonidine; Combined Modality Therapy; Dantrolene; Ergonomic | 2004 |
Consensus panel guidelines for the use of intrathecal baclofen therapy in poststroke spastic hypertonia.
Topics: Baclofen; Humans; Injections, Spinal; Muscle Relaxants, Central; Muscle Spasticity; Practice Guideli | 2006 |
Intrathecal baclofen in the management of post-stroke hypertonia: current applications and future directions.
Topics: Baclofen; Humans; Injections, Spinal; Muscle Hypertonia; Muscle Relaxants, Central; Stroke | 2007 |
Intrathecal baclofen in the treatment of post-stroke central pain, dystonia, and persistent vegetative state.
Topics: Baclofen; Dystonia; Humans; Muscle Relaxants, Central; Pain; Persistent Vegetative State; Stroke | 2007 |
10 trials available for baclofen and Apoplexy
Article | Year |
---|---|
[Combination of central and peripheral muscle relaxants in the treatment of post-stroke spasticity].
Topics: Baclofen; Botulinum Toxins, Type A; Humans; Muscle Relaxants, Central; Muscle Spasticity; Stroke; Tr | 2019 |
Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS).
Topics: Adult; Aged; Baclofen; Drug Administration Schedule; Female; Humans; Injections, Spinal; Male; Middl | 2018 |
Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity.
Topics: Administration, Oral; Aged; Baclofen; Benzodiazepines; Clonidine; Dantrolene; Female; Humans; Infusi | 2018 |
Baclofen for stroke patients with persistent hiccups: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Baclofen; Double-Blind Method; Hiccup; Humans; Middle Aged; Outcome Assessment, Health | 2014 |
Comparative study of therapeutic response to baclofen vs tolperisone in spasticity.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Baclofen; Cerebral Palsy; Child; Child, Preschool; Femal | 2017 |
Limitations of intrathecal baclofen for spastic hemiparesis following stroke.
Topics: Adolescent; Adult; Baclofen; Child; Dose-Response Relationship, Drug; Female; GABA Agonists; Gait Di | 2009 |
Effect of intrathecal baclofen bolus injection on lower extremity joint range of motion during gait in patients with acquired brain injury.
Topics: Adult; Ankle Joint; Baclofen; Brain Injuries; Female; Gait; Hip Joint; Humans; Injections, Spinal; J | 2010 |
Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: a preliminary study.
Topics: Adult; Aged; Baclofen; Female; Hemiplegia; Humans; Infusion Pumps, Implantable; Injections, Spinal; | 2003 |
Intrathecal baclofen management of poststroke spastic hypertonia: implications for function and quality of life.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Baclofen; Female; Humans; Infusion Pumps | 2006 |
Intrathecal baclofen for spastic hypertonia from stroke.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Baclofen; Cross-Over Studies; Dose-Response Relationship | 2001 |
21 other studies available for baclofen and Apoplexy
Article | Year |
---|---|
Reasons and Determinants of BoNT-A Treatment Discontinuation in Patients Living with Spasticity: A 10-Year Retrospective Analysis.
Topics: Baclofen; Botulinum Toxins, Type A; Brain Injuries, Traumatic; Humans; Middle Aged; Multiple Scleros | 2022 |
[Effects of Governor Vessel electroacupuncture on chloridion homeostasis in the cortex of rats with limb spasm after cerebral ischemia-reperfusion].
Topics: Animals; Baclofen; Cerebral Cortex; Cerebral Infarction; Electroacupuncture; gamma-Aminobutyric Acid | 2023 |
Sepsis or sympathetics? Paroxysmal sympathetic hyperactivity after pontine stroke.
Topics: Autonomic Nervous System Diseases; Baclofen; Humans; Male; Middle Aged; Pons; Sepsis; Stroke | 2021 |
Effect of oral baclofen on spasticity poststroke: responders versus non-responders.
Topics: Administration, Oral; Adult; Aged; Ankle Joint; Baclofen; Electromyography; Female; Humans; Male; Mi | 2018 |
[Comparative effectiveness of different muscle relaxants in the rehabilitation of post-stroke patients with spasticity].
Topics: Aged; Baclofen; Clonidine; Comparative Effectiveness Research; Dantrolene; Female; Humans; Male; Mus | 2013 |
Effect of intrathecal baclofen bolus injection on ankle muscle activation during gait in patients with acquired brain injury.
Topics: Adolescent; Adult; Ankle; Baclofen; Biomechanical Phenomena; Brain Injuries; Electromyography; Femal | 2015 |
Spasticity.
Topics: Baclofen; Botulinum Toxins; Cerebral Palsy; Humans; Multiple Sclerosis; Muscle Relaxants, Central; M | 2015 |
Intrathecal Baclofen Dosing Regimens: A Retrospective Chart Review.
Topics: Adult; Aged; Baclofen; Brain Injuries; Cerebral Palsy; Dose-Response Relationship, Drug; Female; Hum | 2016 |
Baclofen Toxicity Causing Acute, Reversible Dyskinesia.
Topics: Aged, 80 and over; Back Pain; Baclofen; Coronary Artery Disease; Diabetes Mellitus; Drug Interaction | 2016 |
Long-Term Dosing of Intrathecal Baclofen in the Treatment of Spasticity After Acquired Brain Injury.
Topics: Academic Medical Centers; Adult; Ambulatory Care; Baclofen; Brain Injuries, Traumatic; Cohort Studie | 2017 |
Baclofen successfully abolished prolonged central hyperthermia in a patient with basilar artery occlusion.
Topics: Aged; Baclofen; Body Temperature Regulation; Brain Stem; Female; Fever; Humans; Stroke; Vertebrobasi | 2009 |
Prospective 12-month study of intrathecal baclofen therapy for poststroke spastic upper and lower extremity motor control and functional improvement.
Topics: Activities of Daily Living; Adult; Aged; Baclofen; Female; Humans; Injections, Spinal; Lower Extremi | 2011 |
Intraventricular baclofen as an alternative to intrathecal baclofen for intractable spasticity or dystonia: outcomes and technical considerations.
Topics: Adolescent; Adult; Aged; Baclofen; Brain Injuries; Cerebral Palsy; Child; Child, Preschool; Dystonic | 2012 |
Intrathecal baclofen in subjects with spastic hemiplegia: assessment of the antispastic effect during gait.
Topics: Adult; Ankle; Baclofen; Biomechanical Phenomena; Body Weight; Brain Injuries; Cerebral Palsy; Electr | 2003 |
Pharmacological risks following stroke.
Topics: Animals; Baclofen; Benzodiazepines; Humans; Muscle Relaxants, Central; Muscle Spasticity; Stroke | 2005 |
Efficacy of early use of intrathecal baclofen therapy for treating spastic hypertonia due to acquired brain injury.
Topics: Adolescent; Adult; Aged; Baclofen; Brain Injuries; Child; Disability Evaluation; Drug Delivery Syste | 2005 |
Survey of management of acquired nystagmus in the United Kingdom.
Topics: Amines; Baclofen; Cyclohexanecarboxylic Acids; Drug Utilization; Excitatory Amino Acid Antagonists; | 2007 |
[Efficacy of intrathecal baclofen in the treatment of spasticity in stroke].
Topics: Baclofen; Hemiplegia; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Middle Aged; Mu | 2007 |
Inflammatory mass of an intrathecal catheter in patients receiving baclofen as a sole agent: a report of two cases and a review of the identification and treatment of the complication.
Topics: Adult; Aged; Baclofen; Catheterization; Female; Granuloma; Humans; Inflammation; Infusion Pumps, Imp | 2007 |
Awake insertion of the Bonfils Retromolar Intubation Fiberscope in five patients with anticipated difficult airways.
Topics: Accidents, Traffic; Adult; Aged; Baclofen; Body Size; Cervical Vertebrae; Equipment Design; Fiber Op | 2008 |
Intrathecal baclofen for spasticity caused by thrombotic stroke.
Topics: Baclofen; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Middle Aged; Muscle Relax | 2001 |